Type 2 Diabetes Drugs and Devices Market Report is Segmented by Product Type (Management Devices [Insulin Pumps, Insulin Syringes, and More], Monitoring Devices [Self-Monitoring Blood Glucose, and More], Drugs [Oral Anti-Diabetic Drugs, Insulins, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

The global diabetes devices and drugs market is booming, projected to reach $1.4 trillion by 2033, driven by rising prevalence, technological advancements, and increased healthcare spending. Explore market trends, key players, and regional insights in this comprehensive analysis.

The US diabetes drugs and devices market is booming, projected to surpass $82 billion by 2033, driven by rising diabetes prevalence and innovative treatment advancements. Explore market trends, key players (Novo Nordisk, Medtronic, Abbott), and regional insights in this comprehensive analysis. Recent developments include: June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education., January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.. Notable trends are: Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.

North America Diabetes Devices and Drugs comes with extensive industry analysis of development components, patterns, flows, and sizes. The report calculates present and past market values to forecast potential market management during the forecast period between 2025 - 2033.

Germany's diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). The report offers the value (in USD) and volume (in unit) for the above segments.

In fiscal year 2025, the market value of diabetes testing and diagnosis appliances as well as drugs was forecast to reach about *** billion Japanese yen. The figure was forecast to decrease slightly in fiscal year 2026.

The size of the US Diabetes Drugs and Devices market was valued at USD 60.12 Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.00">> 4.00% during the forecast period. Recent developments include: June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education., January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.

The global market for Diabetes Devices and Drugs is poised for significant expansion, projected to reach a market size of approximately USD 250 billion by 2025, with a Compound Annual Growth Rate (CAGR) of 5% over the forecast period of 2025-2033. This robust growth is underpinned by several key drivers. The increasing prevalence of diabetes worldwide, driven by factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population, is the primary catalyst. Furthermore, advancements in technology, leading to the development of innovative diabetes management devices like continuous glucose monitors (CGMs) and insulin pumps, are significantly enhancing patient care and market penetration. Growing awareness among patients and healthcare providers about the importance of early diagnosis and effective management of diabetes also contributes to market expansion. The integration of digital health solutions and telemedicine further facilitates remote monitoring and personalized treatment, expanding access to care, particularly in emerging economies. The market segmentation reflects a dynamic landscape catering to diverse patient needs. Within Diabetes Devices, continuous glucose monitoring systems and advanced insulin delivery devices are witnessing substantial demand. In the Diabetes Drugs segment, novel therapies targeting different pathways of diabetes management, including GLP-1 receptor agonists and SGLT2 inhibitors, are gaining prominence due to their improved efficacy and safety profiles. The application spectrum spans diagnostic and clinic settings, intensive care units (ICUs) for acute management, and a rapidly growing home healthcare segment, driven by the desire for convenience and self-management. Major players like Medtronic, Abbott Laboratories, Novo Nordisk, and Roche are actively investing in research and development, strategic acquisitions, and market expansion initiatives to capitalize on these growth opportunities. Geographically, North America and Europe currently dominate the market due to high diabetes incidence and advanced healthcare infrastructure, but the Asia Pacific region is expected to exhibit the fastest growth, propelled by increasing healthcare expenditure, rising disposable incomes, and a growing patient base. Here is a comprehensive report description on Diabetes Devices and Drugs, structured as requested:

According to Cognitive Market Research, the global Diabetes Drugs Market was USD 59.1 billion in 2024 and expand at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.

Market Dynamics of Diabetes Drugs Market

Key Drivers for Diabetes Drugs Market

Excessive sugar consumption increases the number of diabetic individuals- Excess sugar consumption raises the risk of developing diabetes. Furthermore, developments in diabetes diagnosis technologies, such as portable glucometers, are driving the diabetes diagnostics market. A glucometer is a compact, portable device used mostly by diabetics to monitor blood glucose. Ascensia Diabetes Care, a global diabetes care company, got FDA certification for its implantable, next-generation Eversense E3 continuous glucose monitoring (CGM) device in February 2022. These guidelines, as well as continuous glucose monitoring (CGM) devices, aid in the diagnosis and treatment of diabetes. As a result, the availability of such improved glucose monitoring devices promotes market growth.

Technological development.

Key Restraints for Diabetes Drugs Market

Strict regulatory environment inhibits market expansion.

Time-consuming approval process. Introduction of Diabetes Drugs Market

Diabetes is a chronic metabolic condition characterized by high blood glucose levels that cause serious damage to the heart, blood vessels, eyes, kidneys, and neurological system. Type 2 diabetes occurs when the body becomes insulin resistant or does not produce enough insulin. Diabetes affects 62 million individuals in the Americas, the majority of whom live in low- and middle-income countries. Diabetes is directly responsible for 284,049 fatalities annually. The global market could become more robust as the diabetic population grows, technological breakthroughs occur, and adoption rates rise in emerging regions. Furthermore, an increase in obesity, sedentary lifestyle adoption, and consumption of unhealthy foods are predicted to increase the incidence of diabetes, hence driving industry expansion. The Diabetes Drugs Market is driven by the rise in the diabetic population, technological improvement, higher sales of innovative medicines, and a growing acceptance rate in developing countries.

The U.S. Diabetes Drugs and Devices Market size was valued at USD 60.12 Billion in 2024 and is projected to reach USD 80.92 Billion by 2032, growing at a CAGR of 3.7% from 2025 to 2032.

Key Market Drivers:

• Increasing Prevalence of Diabetes: The diabetes drugs and devices market in the U.S. is driven by the increasing prevalence of the disease, with over 37.3 million Americans living with diabetes as of 2021. This demand for effective treatment options, including diabetes drugs and monitoring devices, is expected to continue, further boosting market growth, as predicted by the CDC.

• Technological Advancements in Diabetes Management: Technology advancements, such as continuous glucose monitoring (CGM) systems and insulin pumps, are revolutionizing diabetes management, driving market growth. These devices provide precise and convenient ways to manage blood sugar levels, improving quality of life and reducing complications. The American Diabetes Association (ADA) predicts continued growth in the diabetes devices market due to these technologies.

The size of the Mexico Diabetes Drugs and Devices market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 0.00% during the forecast period. Recent developments include: October 2022: Becton, Dickinson, and Company and Biocorp signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology. It is a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes., March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

Discover the booming South Korea diabetes drugs and devices market! This comprehensive analysis reveals key trends, growth drivers, and leading companies shaping this multi-billion dollar sector. Explore market size projections, segment breakdowns, and future opportunities until 2033. Recent developments include: January 2023: Adela (Online Selling website for Abbott FreeStyle Libre in Korea) announced that the freestyle Libre selling price is expected to be raised by 10% in Korea due to a continuous rise in raw materials and inflation., November 2022: AstraZeneca announced new findings from a pre-specified analysis of DELIVER Phase III trial data showing that Farxiga (dapagliflozin) improved symptom burden and health-related quality of life in patients with heart failure and mildly reduced or preserved ejection fraction compared with placebo.. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

Explore insights from Market Research Intellect's Diabetes Care Devices Drugs Market Report, valued at USD 50 billion in 2024, expected to reach USD 75 billion by 2033 with a CAGR of 6.0% during 2026-2033.Uncover opportunities across demand patterns, technological innovations, and market leaders.

Vietnam diabetes drugs and devices market segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

The size of the Japan Diabetes Drugs and Devices market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 3.20% during the forecast period. Recent developments include: March 2023: Health2Sync developed the latest version of the Health2Sync App that integrates insulin data from Mallya Cap (insulin cartridge) developed by Biocorp and commercialized in Japan by Novo Nordisk., September 2022: Japan's health ministry approved Eli Lilly's diabetes drug Mounjaro (tirzepatide). Mitsubishi Tanabe Pharma Corporation distributes and sells Mounjaro in Japan according to its sales collaboration agreement with Eli Lilly Japan, signed in July 2022. The drug is administered in Japan using ATEOS, a single-use autoinjector device.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

Thailand's Diabetes Drugs and Devices Market is Segmented by Drugs (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs) and Devices (Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-Monitoring Blood and Continuous Glucose Monitoring)). The Report Offers the Value (In USD) and Volume (In Unit) for the Above Segments.

The size of the Thailand Diabetes Drugs and Devices market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 5.02% during the forecast period. Recent developments include: August 2023: The successful bid for hosting the "IDF World Diabetes Congress 2025" in Bangkok was announced at a press conference organized by the International Diabetes Federation (IDF), in collaboration with the Diabetes Association of Thailand, the Ministry of Public Health, the Bangkok Metropolitan Administration, and the Thailand Convention and Exhibition Bureau (TCEB)., April 2022: The insulin pen has been approved by the Thailand Food and Drug Administration (TFDA) through the cooperation between Gan & Lee Thai partner and Gan & Lee. The approved Insulin Pen can be used with the Gan & Lee 3mL cartridge insulin penfill. By adjusting the dose knob, patients can set 1-60 units (U) of insulin for administration. The minimum scale of the pen is accurate to 1 unit (U), which can meet the needs of diabetic patients for daily injections.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

The global Diabetes Drugs and Devices market is projected to reach a valuation of approximately USD 150 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2033.

Global Diabetes Devices and Drugs market size 2025 was XX Million. Diabetes Devices and Drugs Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.